The ongoing collaboration between SciSparc Ltd. SPRC and Clearmind Medicine Inc. CMND CMND CWY resulted in the Tuesday filing of three patent applications under the International Patent Cooperation Treaty.
SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system and Clearmind, a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, jointly announced that the three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide.
The patents seek to protect the companies’ psychedelic compound combinations, ensuring exclusive rights to their innovative therapies. This move aims to solidify their market position, attract investments and drive the advancement of psychedelic medicine for mental health treatment.
These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
Executive Insights On Strategic Expansion
“We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset,” said SciSparc's CEO, Oz Adler. “We believe in the added value that CannAmide can offer when combined with various psychedelic compounds that are known for their therapeutic advantages.”
SPRC And CMND Price Action
SPRC's shares were trading 2.74% higher at $4.13 per share and CMND's shares were trading 7.79% lower at $1.42 per share at the time of this writing around 10 AM ET Wednesday.
Related News
- What’s Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?
- Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Photo: Benzinga edit with photo by Photon photo and Jynto on Wikimedia Commons.
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!